share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer WAGNER CHARLES F JR

SEC announcement ·  Feb 27 17:15
Summary by Moomoo AI
Charles F. Wagner Jr., EVP & Chief Financial Officer of Vertex Pharmaceuticals Inc. (VRTX), completed a sale of 3,309 shares of common stock on February 23, 2024. The transaction was carried out at a price of $431.79 per share, resulting in a total value of $1,428,793.11. Following the sale, Wagner's direct holdings in the company amount to 53,583 shares. The sale was conducted to cover the exercise price or tax liability by delivering or withholding securities, as indicated by the transaction code 'F'.
Charles F. Wagner Jr., EVP & Chief Financial Officer of Vertex Pharmaceuticals Inc. (VRTX), completed a sale of 3,309 shares of common stock on February 23, 2024. The transaction was carried out at a price of $431.79 per share, resulting in a total value of $1,428,793.11. Following the sale, Wagner's direct holdings in the company amount to 53,583 shares. The sale was conducted to cover the exercise price or tax liability by delivering or withholding securities, as indicated by the transaction code 'F'.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more